SYNKAYVITE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jul 1941
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYNKAYVITE is an injectable small-molecule product approved in 1941 by Roche, representing a legacy asset with established clinical use. The specific mechanism of action and indication are not publicly detailed in available records, though the injection route and 80+ year history suggest a well-characterized therapeutic class. This product operates in a mature market segment with moderate competitive intensity.
LOE Approaching
LOE-approaching lifecycle signals reduced commercial investment and team contraction; career opportunities focus on managed decline and transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SYNKAYVITE offers limited career growth given its LOE-approaching status and zero linked job openings; opportunities are primarily in defensive commercial roles (sales, marketing operations) managing a declining portfolio asset. This role suits professionals seeking stability in a mature product with predictable, low-volatility responsibilities rather than innovation-focused advancement.
Brand Manager
Worked on SYNKAYVITE at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.